Bristol Myers Squibb (BMS) will showcase new clinical and real-world findings from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress 2025, held August 29 – September 1 in Madrid, Spain.
Data highlights include:
- Real-world analyses of Camzyos® (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Clinical data from the BMS-Pfizer Alliance on Eliquis® (apixaban).
Commitment to Cardiovascular Innovation
“With a 70-year legacy in cardiovascular medicine, we are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM,”
- Roland Chen, MD, senior vice president, drug development, immunology and cardiovascular medicines at BMS.
He continued:
“Camzyos is the first and only available cardiac myosin inhibitor supported by robust long-term extension and real-world effectiveness data in patients with oHCM. Clinical studies have shown symptom relief, improved functional capacity, and positive effects on cardiac structure, both with and without background therapy. We look forward to sharing new data at this year’s ESC Congress, building on real-world evidence that reinforces its safety profile and benefits for diverse patients worldwide.”
Key Data Presentations
At ESC Congress 2025, BMS will deliver multiple oral presentations:
- Real-world outcomes for Camzyos (COLLIGO-HCM study)
- A global observational study across the US, Canada, UK, Australia, and Israel.
- Reflects diverse patient populations treated for symptomatic oHCM. - Camzyos monotherapy pooled analysis
- Combines results from four phase 3 studies.
- Evaluates efficacy and safety in oHCM patients without background therapy. - ODYSSEY-HCM trial results (late-breaking)
- Phase 3, randomized, double-blind, placebo-controlled study in 580 adults with symptomatic NYHA class II–III non-obstructive HCM (nHCM).
- The largest and longest-duration study completed to date in this patient group.
About Camzyos (Mavacamten)
- First and only cardiac myosin inhibitor approved in the US.
- Indications:
- US: Treatment of adults with symptomatic NYHA class II–III obstructive HCM to improve functional capacity and symptoms.
- EU: Approved for symptomatic NYHA class II–III oHCM in adults. - Approved in 50+ countries and regions across five continents.
Mechanism of Action:
- Camzyos is a selective, reversible, allosteric inhibitor of cardiac myosin.
- It modulates the number of myosin heads binding to actin, reducing:
- Systolic force production
- Diastolic cross-bridge formation - Shifts myosin into an energy-sparing, super-relaxed state.
- In oHCM patients, this results in:
- Reduced LVOT obstruction
- Improved cardiac filling pressures
- Better symptom control and functional capacity.
About Eliquis (Apixaban)
- Oral selective Factor Xa inhibitor that reduces thrombin generation and clot formation.
- Approved indications in the US include:
- Reducing risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF).
- DVT prophylaxis in adults after hip or knee replacement surgery.
- Treatment of DVT and PE in adults.
- Reducing risk of recurrent DVT and PE following initial therapy.
- Paediatric VTE treatment (from birth and older) after at least 5 days of initial anticoagulant therapy. - Backed by multiple phase 3 trials.
- Commercialized globally by the BMS-Pfizer Alliance.
About Bristol Myers Squibb
Bristol Myers Squibb’s mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company is pursuing bold science to expand the possibilities of medicine and improve outcomes for patients worldwide.
